Compare Biocon with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON VENUS REMEDIES BIOCON /
VENUS REMEDIES
 
P/E (TTM) x 45.1 6.5 699.6% View Chart
P/BV x 5.6 1.4 411.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 BIOCON    VENUS REMEDIES
EQUITY SHARE DATA
    BIOCON
Mar-21
VENUS REMEDIES
Mar-21
BIOCON /
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs488314 155.3%   
Low Rs27522 1,236.7%   
Sales per share (Unadj.) Rs59.2444.2 13.3%  
Earnings per share (Unadj.) Rs7.750.1 15.4%  
Cash flow per share (Unadj.) Rs13.778.6 17.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs62.3313.2 19.9%  
Shares outstanding (eoy) m1,200.0012.34 9,724.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x6.40.4 1,699.9%   
Avg P/E ratio x49.43.4 1,470.9%  
P/CF ratio (eoy) x27.92.1 1,303.6%  
Price / Book Value ratio x6.10.5 1,139.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m457,3502,075 22,037.7%   
No. of employees `000NANA-   
Total wages/salary Rs m17,410460 3,783.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m71,0585,481 1,296.4%  
Other income Rs m6,052196 3,083.0%   
Total revenues Rs m77,1105,678 1,358.2%   
Gross profit Rs m13,145772 1,702.3%  
Depreciation Rs m7,151353 2,027.2%   
Interest Rs m577130 443.2%   
Profit before tax Rs m11,469486 2,362.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,215-132 -1,676.5%   
Profit after tax Rs m9,254618 1,498.3%  
Gross profit margin %18.514.1 131.3%  
Effective tax rate %19.3-27.2 -71.0%   
Net profit margin %13.011.3 115.6%  
BALANCE SHEET DATA
Current assets Rs m76,0042,316 3,281.8%   
Current liabilities Rs m42,101974 4,320.5%   
Net working cap to sales %47.724.5 194.9%  
Current ratio x1.82.4 76.0%  
Inventory Days Days13725 547.4%  
Debtors Days Days63213 29.3%  
Net fixed assets Rs m106,1423,243 3,273.4%   
Share capital Rs m6,000123 4,861.4%   
"Free" reserves Rs m68,7283,742 1,836.7%   
Net worth Rs m74,7283,865 1,933.3%   
Long term debt Rs m29,616468 6,324.0%   
Total assets Rs m182,1465,559 3,276.9%  
Interest coverage x20.94.7 441.4%   
Debt to equity ratio x0.40.1 327.1%  
Sales to assets ratio x0.41.0 39.6%   
Return on assets %5.413.5 40.1%  
Return on equity %12.416.0 77.5%  
Return on capital %11.514.2 81.3%  
Exports to sales %00-   
Imports to sales %7.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m5,084NA-   
Fx inflow Rs m11,7910-   
Fx outflow Rs m5,0840-   
Net fx Rs m6,7070-   
CASH FLOW
From Operations Rs m11,5971,326 874.5%  
From Investments Rs m-36,247557 -6,505.7%  
From Financial Activity Rs m25,640-1,622 -1,580.3%  
Net Cashflow Rs m723269 268.4%  

Share Holding

Indian Promoters % 39.7 40.8 97.4%  
Foreign collaborators % 20.9 0.0 -  
Indian inst/Mut Fund % 23.4 0.3 8,346.4%  
FIIs % 16.0 0.3 5,714.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 59.2 66.5%  
Shareholders   364,502 18,231 1,999.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    AUROBINDO PHARMA    



Today's Market

Sensex Tanks 554 Points, Nifty Ends Near 18,100; Maruti, Tech Mahindra & Tata Consumer Plunge 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

VENUS REMEDIES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 2, 2021 | Updated on Nov 2, 2021

Here's an analysis of the annual report of VENUS REMEDIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

BIOCON Announces Quarterly Results (2QFY22); Net Profit Up 4.9% (Quarterly Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

For the quarter ended September 2021, BIOCON has posted a net profit of Rs 2 bn (up 4.9% YoY). Sales on the other hand came in at Rs 18 bn (up 5.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Looking for Consistent Compounding Stocks? Here's a Watchlist for You(Views On News)

Jan 6, 2022

These companies have generated mind boggling returns for investors over the years.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 18, 2022 03:35 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS